Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4798477 | 0.98 | CYP1A2 (1.00) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| SCHEMBL1372 | 0.98 | CYP1A2 (1.00) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| Hydrochloric Acid SCHEMBL1595766 | 0.96 | CYP1A2 (0.96) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| Ammonia Solution, Strong SCHEMBL21805838 | 0.96 | CYP1A2 (0.96) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| Iodide SCHEMBL660783 | 0.96 | CYP1A2 (0.96) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| Hydrochloric Acid SCHEMBL2761 | 0.96 | CYP1A2 (0.96) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| SCHEMBL2597843 | 0.96 | CYP1A2 (0.96) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| Bromide SCHEMBL22418547 | 0.96 | CYP1A2 (0.96) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| Water SCHEMBL1475933 | 0.96 | CYP1A2 (0.96) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 | |
| SCHEMBL31435659 | 0.96 | CYP1A2 (0.96) | CYP1A2CYP2D6ALDH1A1TSHRDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2018-12-27 | — | — | US | disclosed |
| US-9873693-B2 | Methods of treatment using pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| CN-101541783-B | pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-10-01 | — | — | CN | disclosed |
| US-8778977-B2 | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| EP-2038272-B1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-1702919-B1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | SUNESIS PHAMACEUTICALS (US) | 2010-06-10 | — | — | US | disclosed |
| US-7728025-B2 | 2-heteroaryl-substituted benzimidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| CN-101541783-A | Pyridinonyl PDK1 inhibitors | SUNESIS PHARMACEUTICALS (US) | 2009-09-23 | — | — | CN | disclosed |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370966-A1 | METHODS OF TREATMENT USING PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | CYP1A2 4714/4885CYP2D6 4419/4885ALDH1A1 2166/4885 |
| US-20100144730-A1 | PYRIDINONYL PDK1 INHIBITORS | PDK1, PDK2, PDK3 | CYP1A2 4561/4885CYP2D6 4169/4885ALDH1A1 1905/4885 |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | GCK, GCKR, HK1 | CYP1A2 2216/4885CYP2D6 1491/4885ALDH1A1 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.